Sai Life Sciences Bulk Deal: TPG Exits Via Rs 2,675-Crore Sale
US private equity firm TPG, a prominent public shareholder of Sai Life Sciences Ltd., has made a complete exit from the company in a bulk deal worth Rs 2,675 crore, as per NSE bulk data.
TPG affiliate TPG Asia VII SF Pte offloaded 3.07 crore shares (14.72%) between Rs 871.01 to Rs 871.86 apiece; while Societe Generale bought 14.06 lakh shares (0.67%) at Rs 871 apiece, Goldman Sachs (Singapore) Pte bought 11.04 lakh shares (0.53%) at Rs 871 apiece.
Deal Details
IIFL Capital Services Ltd., Kotak Securities Ltd. and Jefferies India Pvt. were the bookrunners for the deal.
The public shareholder owned 24.73% stake in the company, as per BSE data recorded until March 31, 2025. However, it offloaded 10% of its shares at Rs 722 per piece. This was after 48% equity of Sai Life Sciences became eligible for trade as the six-month lock-in period ends for shareholders, as per Nuvama’s report.
About Sai Life Sciences
Sai Life Sciences is an innovator-focused contract research, development, and manufacturing organisation based in Hyderabad.
The company offers comprehensive end-to-end services across the entire drug discovery, development and manufacturing value chain. Specialising in small molecule new chemical entities, Sai Life Sciences caters to global pharmaceutical and biotechnology companies.
Impact on Indian Pharmaceutical Sector
The deal is expected to have a positive impact on the Indian pharmaceutical sector, with many companies looking to expand their operations and increase their market share.
According to a report by ICRA, the Indian pharmaceutical sector is expected to grow at a CAGR of 10-12% over the next five years, driven by increasing demand for healthcare services and a growing population.
Investment Opportunities
The deal highlights the investment opportunities available in the Indian pharmaceutical sector, with many companies looking to expand their operations and increase their market share.
Investors looking to invest in the sector can consider companies such as Sun Pharmaceutical, Cipla, and Dr. Reddy’s Laboratories, which are some of the leading players in the sector.
Conclusion
In conclusion, the bulk deal by TPG in Sai Life Sciences highlights the growing interest in the Indian pharmaceutical sector, with many companies looking to expand their operations and increase their market share.
Investors looking to invest in the sector can consider companies such as Sun Pharmaceutical, Cipla, and Dr. Reddy’s Laboratories, which are some of the leading players in the sector.